Long-Term CARTITUDE-4 Study Update in MM
October 25th 2024Panelists discuss how data from the long-term CARTITUDE-4 study update in multiple myeloma (MM) highlight the sustained efficacy and safety of ciltacabtagene autoleucel, reinforcing its role as a promising treatment option for patients with lenalidomide-refractory disease.
Overview of CARTITUDE-4: Study Design, Baseline Characteristics, and Efficacy
October 18th 2024Panelists discuss how the CARTITUDE-4 study data provide a comprehensive overview of its design, baseline characteristics, and efficacy outcomes, highlighting the potential of ciltacabtagene autoleucel in improving treatment results for patients with lenalidomide-refractory multiple myeloma.
Impact of CAR T-Cell Therapy in R/R MM
October 11th 2024Panelists discuss how chimeric antigen receptor (CAR) -T-cell therapy has transformed the treatment landscape for relapsed/refractory multiple myeloma (R/R MM), demonstrating remarkable efficacy and offering new hope for patients with limited therapeutic options.
Collaborative Care vs. Independent Treatment: Does It Impact Patient Outcomes in Multiple Myeloma?
October 11th 2024Panelists discuss how collaborative care settings for multiple myeloma patients often lead to improved outcomes compared to non-collaborative approaches, citing factors such as access to specialized expertise, coordinated treatment plans, and comprehensive patient support.